NPM1 is the most frequently mutated gene in adults with acute myeloid leukemia (AML). The interaction between mutant NPM1 (NPM1c) and exportin-1 (XPO1) causes aberrant cytoplasmic dislocation of NPM1c and promotes the high expression of homeobox (HOX) genes, which is critical for maintaining the leukemic state of NPM1-mutated cells. Although there is a rationale for using XPO1 inhibitors in NPM1-mutated AML, selinexor administered once or twice per week did not translate into clinical benefit in patients with NPM1 mutations. Here, we show that this dosing strategy results in only a temporary disruption of the XPO1-NPM1c interaction, limiting the efficacy of selinexor. Because the second-generation XPO1 inhibitor eltanexor can be administered more frequently, we tested the antileukemic activity of prolonged XPO1 inhibition in NPM1-mutated AML models. Eltanexor caused irreversible HOX downregulation, induced terminal AML differentiation, and prolonged the survival of leukemic mice. This study provides essential information for the appropriate design of clinical trials with XPO1 inhibitors in NPM1-mutated AML.

Pianigiani, G., Gagliardi, A., Mezzasoma, F., Rocchio, F., Tini, V., Bigerna, B., Sportoletti, P., Caruso, S., Marra, A., Peruzzi, S., Petito, E., Spinozzi, G., Shacham, S., Landesman, Y., Quintarelli, C., Gresele, P., Locatelli, F., Martelli, M. P., Falini, B., Brunetti, L., Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML, <<BLOOD ADVANCES>>, 2022; 6 (22): 5938-5949. [doi:10.1182/bloodadvances.2022007563] [https://hdl.handle.net/10807/228429]

Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML

Locatelli, Franco
Writing – Review & Editing
;
2022

Abstract

NPM1 is the most frequently mutated gene in adults with acute myeloid leukemia (AML). The interaction between mutant NPM1 (NPM1c) and exportin-1 (XPO1) causes aberrant cytoplasmic dislocation of NPM1c and promotes the high expression of homeobox (HOX) genes, which is critical for maintaining the leukemic state of NPM1-mutated cells. Although there is a rationale for using XPO1 inhibitors in NPM1-mutated AML, selinexor administered once or twice per week did not translate into clinical benefit in patients with NPM1 mutations. Here, we show that this dosing strategy results in only a temporary disruption of the XPO1-NPM1c interaction, limiting the efficacy of selinexor. Because the second-generation XPO1 inhibitor eltanexor can be administered more frequently, we tested the antileukemic activity of prolonged XPO1 inhibition in NPM1-mutated AML models. Eltanexor caused irreversible HOX downregulation, induced terminal AML differentiation, and prolonged the survival of leukemic mice. This study provides essential information for the appropriate design of clinical trials with XPO1 inhibitors in NPM1-mutated AML.
2022
Inglese
Pianigiani, G., Gagliardi, A., Mezzasoma, F., Rocchio, F., Tini, V., Bigerna, B., Sportoletti, P., Caruso, S., Marra, A., Peruzzi, S., Petito, E., Spinozzi, G., Shacham, S., Landesman, Y., Quintarelli, C., Gresele, P., Locatelli, F., Martelli, M. P., Falini, B., Brunetti, L., Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML, <<BLOOD ADVANCES>>, 2022; 6 (22): 5938-5949. [doi:10.1182/bloodadvances.2022007563] [https://hdl.handle.net/10807/228429]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/228429
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 13
social impact